Precision Medicine · global
Roche’s Two HER2 Tests Gain Expanded Approval to Support First-Line Ziihera Treatment for Gastroesophageal Cancer
Even among HER2-positive patients, protein expression and genetic test results can affect treatment eligibility. The FDA has expanded the approved uses of Roche’s companion diagnostics, providing corresponding pathology-based screening criteria for new treatments for gastric, gastroesophageal junction, and esophageal adenocarcinoma.
For patients with advanced gastroesophageal adenocarcinoma, whether a new drug becomes a treatment option often depends first on signals in a tissue section. On August 25, 2026, the U.S. Food and Drug Administration (FDA) approved a new indication for Ziihera and expanded the uses of two Roche HER2 companion diagnostics, linking tumors’ molecular characteristics to treatment eligibility.
Roche announced on August 27 that PATHWAY HER2 (4B5) and VENTANA HER2 Dual ISH DNA Probe Cocktail can be used to identify patients eligible for treatment with Jazz Pharmaceuticals’ Ziihera (zanidatamab-hrii), covering gastric, gastroesophageal junction, and esophageal adenocarcinoma. According to the FDA announcement, the new treatment is indicated as first-line therapy for adults with unresectable locally advanced or metastatic disease.
The two tests answer complementary questions. PATHWAY uses immunohistochemistry (IHC) to assess HER2 protein expression in tumors, while VENTANA Dual ISH uses in situ hybridization to detect HER2 gene amplification. When the IHC result is 2+, ISH positivity must also be confirmed to meet the HER2-positive criteria for some of the regimens covered by this approval. This also illustrates why a staining score alone may not be sufficient to determine treatment eligibility.
The approval criteria vary by regimen. Ziihera combined with tislelizumab (Tevimbra) and fluoropyrimidine- and platinum-containing chemotherapy can be used in patients with IHC 3+ or IHC 2+/ISH+ results. If Ziihera is combined with chemotherapy without tislelizumab, eligibility is limited to IHC 3+. Details in the test report therefore directly determine which approved regimen a patient qualifies for.
The clinical evidence supporting this drug approval came from the phase 3 HERIZON-GEA-01 trial, in which 914 patients were randomized into three groups. The FDA stated that median overall survival was 26.4 months in the Ziihera, tislelizumab, and chemotherapy group, compared with 19.2 months in the trastuzumab plus chemotherapy control group. Median progression-free survival was 12.4 and 8.1 months, respectively. However, the Ziihera plus chemotherapy group had not achieved a statistically significant difference in overall survival at the interim analysis at that time, so the evidence for the different regimens cannot be treated as equivalent.
In the laboratory, PATHWAY can be integrated into Roche’s automated VENTANA BenchMark slide staining platform, while Dual ISH provides gene amplification information to assist pathologists in their interpretation. This expansion concerns the approved uses of existing tests. Its significance lies in supporting patient selection for new treatments; a positive test does not guarantee that treatment will be effective.
Treatment benefits must also be weighed against risks. The Ziihera prescribing information listed by the FDA includes boxed warnings for diarrhea and embryo-fetal toxicity, as well as warnings and precautions concerning left ventricular dysfunction and infusion reactions. From tissue interpretation to regimen selection, this approval makes the criteria for directing patients to treatment clearer. Whether an individual patient benefits still depends on their overall clinical condition, treatment tolerability, and subsequent response.